TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Dr. Tawanda Gumbo

Listen to Tawanda Gumbo Podcast

Summary: Dr. Tawanda Gumbo, an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.” The paper puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB but instead that the differences or fluctuations in the way patients absorb, metabolize and retain the drug in their bodies contributes to the emergence of resistance to TB drugs. In this interview, we discuss the recently published paper, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.

Dr. Gumbo’s research is focused on advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics, clinical trial simulations using Monte Carlo Methods, individualized Bayesian dose optimization, as well as, the molecular and cellular pharmacology of antituberculosis and other antimycobacterial agents.

Additional TB R&D News:

Recent exchange on the topic of Moxifloxacin use:

Rational use of moxifloxacin for tuberculosis treatment

Moxifloxacin for tuberculosis (Mendel & Springsklee)

Moxifloxacin for tuberculosis (Singh, et al.)

Moxifloxacin for tuberculosis — Authors’ reply

Other news links:

SymptomsofTuberculosis.Net Launches to Address Rising Concerns Over Tuberculosis and Symptoms of Tuberculosis

Biomedical company sets up in Memphis

Combating TB, the right way

Polio eradication has a lesson for TB control

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...